mercredi 5 juin 2019

Onco Actu du 5 juin 2019


1. BIOLOGIE



Early Genome Catastrophes Can Cause Non-Smoking Lung Cancer [KAIST]











1.4 BIOLOGIE - TECHNOS



Watching cancer cells evolve through chromosomal instability [Nature]










5.12 IMMUNOTHÉRAPIES



GITR Is an Attractive Target for Immunotherapy [ESMO]











5.17 TRAITEMENTS - RADIOTHÉRAPIE



New late stage prostate cancer technology available in UK [Pharma Times]











5.2 PHARMA



Pfizer, late on immunotherapy, charts faster course for targeted drugs [Biopharma Dive]











5.2.3 PHARMA - ÉCONOMIE



Weeks after raising $40M, Celgene-partnered Inhibrx lays groundwork for nearly $75M public debut [EndPoints]











5.5.1.1 ASCO (GÉNÉRAL) - INDUSTRIELS



ASCO: AstraZeneca's Baselga on tailoring treatments and the march to cure cancer [Fierce Biotech]











ASCO Soundbites, vol. 3: Real-time approvals, Pfizer's second rodeo and 'the busiest ASCO ever' [Fierce Pharma]











Biotech, pharma stocks climb higher after cancer meeting [Biopharma Dive]











5.5.10 ASCO (HÉMATO)



Lymphoma trial finds combination targeted therapy effective prior to chemotherapy [MD Anderson Cancer Center]











AbbVie unveils Venclexta data that scored lightning-fast leukemia combination nod [Fierce Pharma]











ASCO Highlights for Tuesday June 4, 2019 [OBR]











Pivotal phase III CLL14 results for Venclexta/Venclyxto in combination with Gazyva/Gazyvaro for chronic lymphocytic leukaemia presented at ASCO 2019 and published in the New England Journal of Medicine [Roche]











5.5.16 ASCO (MÉDECINE DE PRÉCISION)



At ASCO, Real-World Data Shows Potential to Improve Precision Oncology [Genome Web]











ASCO's hot marketing topics: Real-world data, competition and differentiation, analyst says [Fierce Pharma]











How Real-World Data Can Impact NSCLC Treatment [AJMC]











5.5.2 ASCO (SEIN)



Puma Biotechnology Presents Results from Phase III NALA Trial of Neratinib in Patients with HER2-Positive Metastatic Breast Cancer at the ASCO 2019 Annual Meeting [Puma]











5.5.3 ASCO (PROSTATE)



Men with early-stage prostate cancer who choose active surveillance often don’t follow monitoring guidelines [UNC Lineberger]











ASCO 2019: Breast cancer drug effective in 80 per cent of men with BRCA-mutant prostate cancer [Institute of Cancer Research]











5.5.4.5 ASCO (IMMUNOTHÉRAPIES-CAR-T, THÉRAPIES CELLULAIRES)



Celgene Announces Data from Ongoing Studies of Liso-Cel in Patients with Difficult-to-Treat Blood Cancers at ASCO 2019 [Celgene]











5.5.5 ASCO (GASTRO-INTESTINAL)



Immunoscore® Demonstrates Clinical Utility In Stage III Colon Cancer [HalioDx]











5.5.6 ASCO (PEAU-MÉLANOME)



Long-term survival benefit shown for metastatic melanoma patients treated with Novartis Tafinlar® + Mekinist® [Novartis]











5.5.8 ASCO (POUMON)



#ASCO19: MET inhibitors from Incyte/Novartis and Germany's Merck face off for rare subset of NSCLC patients [EndPoints]











6. LUTTE CONTRE LES CANCERS



ASCO Remembers Cancer Genetics Pioneer Dr. Henry T. Lynch [ASCO Connection]











6.11 PATIENTS



Jo Taylor: It’s time to call time on “The end of treatment bell” [BMJ]











6.6 PUBLICATIONS



Plan Universal calls on funders to encourage preprints [Cold Spring Harbor Lab]











“Our current approaches are not working:” Time to make misconduct investigation reports public, says integrity expert [Retraction Watch]











Plan U: Universal access to scientific and medical research via funder preprint mandates [PLoS Biology]










6.7 DMP, BIG DATA & APPLIS



Credit data generators for data reuse [Nature]










6.8 COMMUNICATION



Three randomized controlled trials evaluating the impact of “spin” in health news stories reporting studies of pharmacologic treatments on patients’/caregivers’ interpretation of treatment benefit [BMC Medicine]